Compare Amgen, Inc. (AMGN) vs Walmart Stores Inc (WMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Walmart Stores Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Walmart Stores Inc trades at $114.48 (market cap $906.43B). The key difference: Walmart Stores Inc is far larger — about 4.6× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | WMT | |
|---|---|---|
Market Cap | $196.12B | $906.43B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $134.20 |
52-Week Low | $271.18 | $94.40 |
Enterprise Value | $241.41B | $969.88B |
Dividend Yield | 2.77% | 0.87% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Walmart (WMT) trades at $113.9, up 1.51% today, amid mixed signals. The stock shows bearish technical indicators but strong fundamentals with consistent earnings beats and revenue growth to $681.0 billion in 2025. Recent news highlights Walmart's AI initiatives and philanthropic efforts, while competition intensifies as Amazon surpasses it in Fortune 500 revenue ranking.
The outlook remains positive with a consensus price target of $141.64, implying significant upside. Risks include competitive pressures and economic sensitivity, but Walmart's scale, dividend stability, and operational efficiency support a bullish long-term view for investors seeking defensive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
